Abu-Lubad Mohammad A, Abu-Helalah Munir A, QawaQzeh Mohammad S, Alahmad Esra'a F, Al-Tamimi Malak M, Ruba'I Mohammad K, Etoom Sahm H, Alfayoumi Rawan K, Aldaoudeyeh Fatima E, AlAbabneh Ekram A, Al-Kharabsheh Ahlam M, Alshraideh Hussam
Department of Microbiology and Pathology, Faculty of Medicine, Mutah University, P.O. Box 7 Mutah, Al-Karak, 61710, Jordan.
Department of Family and Community Medicine, School of Medicine, University of Jordan, Public Health Institute, Amman, Jordan.
J Egypt Public Health Assoc. 2024 Apr 10;99(1):8. doi: 10.1186/s42506-024-00153-z.
Several recent studies have highlighted the need for more evaluation of the impact of COVID-19 infections and vaccines on the reproductive system and menstruation. This study aimed to assess the impact of COVID-19 infection and vaccines on menstrual symptoms.
A cross-sectional survey utilizing face-to-face interviews from January 1 to 31 March 2022 was conducted in the city of Al-Karak in southern Jordan. The questionnaire included sociodemographic characteristics, medical and reproductive history, the contraceptive method used if any, menstrual cycle (MC) status, previous medical and drug history, and the impact of infection and vaccination on the MC.
The study questionnaire was completed by 400 participants with a mean age of 32.1±12.6 years. Regarding the history of COVID-19 infections, 33.8% of the participants reported a history of confirmed COVID-19 infections, 77.8% of them did not report any menstrual changes following the infection, while the remaining 22.2% reported changes in menstruation. The most commonly reported post-COVID-19 manifestations were irregular (27.6%) and light menstrual cycle (MC) (24.15) or dysmenorrhea (24.1%). Heavy menstruation was reported by 17.2% of participants post-COVID-19 infection. Two-thirds of the study participants (66.6%) reported no changes in the MC following the administration of the COVID-19 vaccine. The most reported symptoms for those who experienced changes in the MC following the vaccination were irregular cycle (13.1%), heavy menstruation (7%), and light menstruation (7%). Other reported symptoms were dysmenorrhea (4.6%), intermenstrual bleeding (1.2%), and amenorrhea (0.5%).
This study revealed minor changes in the MC following COVID-19 infections and administration of the COVID-19 vaccine. These findings are consistent with published reports. It is recommended that future clinical trials for new vaccines for women of childbearing age include outcomes related to sex hormones and MC. Women should be encouraged to take the vaccines and report symptoms to healthcare professionals for further assessment.
最近的几项研究强调,需要对新冠病毒感染和疫苗对生殖系统及月经的影响进行更多评估。本研究旨在评估新冠病毒感染和疫苗对月经症状的影响。
2022年1月1日至3月31日,在约旦南部的卡拉克市进行了一项采用面对面访谈的横断面调查。问卷包括社会人口学特征、医疗和生殖史、使用的避孕方法(如有)、月经周期(MC)状况、既往医疗和用药史,以及感染和接种疫苗对月经周期的影响。
400名参与者完成了研究问卷,平均年龄为32.1±12.6岁。关于新冠病毒感染史,33.8%的参与者报告有确诊的新冠病毒感染史,其中77.8%的人在感染后未报告任何月经变化,其余22.2%的人报告有月经变化。新冠病毒感染后最常报告的表现是月经不规律(27.6%)、月经周期缩短(24.15%)或痛经(24.1%)。17.2%的参与者在新冠病毒感染后报告月经量过多。三分之二的研究参与者(66.6%)报告在接种新冠病毒疫苗后月经周期没有变化。接种疫苗后月经周期发生变化的人中,最常报告的症状是月经周期不规律(13.1%)、月经量过多(7%)和月经量减少(7%)。其他报告的症状包括痛经(4.6%)、经间期出血(1.2%)和闭经(0.5%)。
本研究揭示了新冠病毒感染和接种新冠病毒疫苗后月经周期的轻微变化。这些发现与已发表的报告一致。建议未来针对育龄女性的新疫苗临床试验纳入与性激素和月经周期相关的结果。应鼓励女性接种疫苗,并向医护人员报告症状以便进一步评估。